{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:57:23Z","timestamp":1740135443942,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Restless Legs Syndrome (RLS) is a sensorimotor disorder characterized by unpleasant and distressing sensations in the lower limbs that are more pronounced in the evening, commence or worsen at rest, and show partial or complete relief following movement. It can occur as a primary disorder, secondary to medical conditions or treatment with medications including but not limited to antidepressants or antipsychotics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 32-year old man with major depressive disorder showed partial response to Escitalopram 10\u2009mg daily. Agomelatine 25\u2009mg at night was added to Escitalopram to treat his residual depressive symptoms, namely insomnia and tiredness. Within two days he developed restlessness and unpleasant sensations in his legs which were worse at night. Symptom severity increased over the following days, prompting an urgent consultation a week later. The patient\u2019s presentation met the criteria for RLS. Agomelatine was discontinued leaving the patient on Escitalopram alone. The patient\u2019s symptoms improved within 24\u2009h of stopping Agomelatine, with complete resolution four days later. There was no recurrence of RLS during follow-up. The patient scored 6 on Naranjo\u2019s adverse drug reaction probability scale, indicating a probable adverse drug reaction caused by Agomelatine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>To the best of our knowledge, this is the first case report of suspected Agomelatine-induced RLS. Clinicians need to be aware of RLS to enable prompt diagnosis and management. We suggest adding Agomelatine to the list of agents that can potentially induce RLS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-021-03175-5","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T07:03:09Z","timestamp":1617778989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Suspected Agomelatine-induced restless legs syndrome: a case report"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0497-1528","authenticated-orcid":false,"given":"Mustafa","family":"Abdul Karim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9944-6130","authenticated-orcid":false,"given":"Nadeen","family":"Al-Baz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-060X","authenticated-orcid":false,"given":"Sami","family":"Ouanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2650","authenticated-orcid":false,"given":"Majid","family":"Alabdulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3383-9294","authenticated-orcid":false,"given":"Peter M.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"3175_CR1","unstructured":"International Restless Legs Syndrome Study Group - Diagnostic Criteria. Available from: http:\/\/www.irlssg.org\/Diagnostic-Criteria. [cited 2020 Sep 22]"},{"key":"3175_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s11325-011-0606-x","volume":"16","author":"P Yeh","year":"2012","unstructured":"Yeh P, Walters AS, Tsuang JW. Restless legs syndrome: A comprehensive overview on its epidemiology, risk factors, and treatment. Sleep Breath. 2012;16:987\u20131007 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22038683\/ [cited 2020 Sep 17].","journal-title":"Sleep Breath"},{"issue":"2","key":"3175_CR3","doi-asserted-by":"publisher","first-page":"e2504","DOI":"10.1097\/MD.0000000000002504","volume":"95","author":"GJ Liu","year":"2016","unstructured":"Liu GJ, Wu L, Wang SL, Ding L, Xu LL, Wang YF, et al. Incidence of Augmentation in Primary Restless Legs Syndrome Patients May Not Be That High. Medicine (Baltimore). 2016;95(2):e2504 Available from: http:\/\/journals.lww.com\/00005792-201601120-000741 [cited 2020 Sep 27].","journal-title":"Medicine (Baltimore)"},{"key":"3175_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.smrv.2011.05.002","volume":"16","author":"MM Ohayon","year":"2012","unstructured":"Ohayon MM, O\u2019Hara R, Vitiello MV. Epidemiology of restless legs syndrome: A synthesis of the literature. Sleep Med Rev. 2012;16:283\u201395 W.B. Saunders.","journal-title":"Sleep Med Rev"},{"key":"3175_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fnagi.2017.00171","volume":"9","author":"S Guo","year":"2017","unstructured":"Guo S, Huang J, Jiang H, Han C, Li J, Xu X, et al. Restless legs syndrome: From pathophysiology to clinical diagnosis and management. Front Aging Neurosci. 2017;9:171 Available from: \/pmc\/articles\/PMC5454050\/?report=abstract [cited 2020 Sep 22]. Frontiers Media S.A.","journal-title":"Front Aging Neurosci"},{"key":"3175_CR6","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.2147\/NDT.S161583","volume":"15","author":"E Ruppert","year":"2019","unstructured":"Ruppert E. Restless arms syndrome: Prevalence, impact, and management strategies. Neuropsychiatr Dis Treat. 2019;15:1737\u201350 Available from: \/pmc\/articles\/PMC6612954\/?report=abstract [cited 2020 Sep 24].","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"3175_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1389-9457(02)00258-7","volume":"4","author":"J Horiguchi","year":"2003","unstructured":"Horiguchi J, Hornyak M, Voderholzer U, Kryger M, Skomrow R, Lipinski JF, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4(2):121\u201332 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/14592342\/ [cited 2020 Sep 13].","journal-title":"Sleep Med"},{"issue":"8","key":"3175_CR8","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ng2099","volume":"39","author":"J Winkelmann","year":"2007","unstructured":"Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet. 2007;39(8):1000\u20136 Available from: http:\/\/www.nature.com\/articles\/ng2099 [cited 2020 Sep 24].","journal-title":"Nat Genet"},{"key":"3175_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/2047-9158-1-6","volume":"1","author":"T Peeraully","year":"2012","unstructured":"Peeraully T, Tan EK. Linking restless legs syndrome with Parkinson\u2019s disease: clinical, imaging and genetic evidence. Transl Neurodegener. 2012;1:6 Available from: https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/2047-9158-1-6 [cited 2020 Sep 25]. BioMed Central.","journal-title":"Transl Neurodegener"},{"key":"3175_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jsmc.2015.05.022","volume":"10","author":"RP Allen","year":"2015","unstructured":"Allen RP. Restless Leg Syndrome\/Willis-Ekbom Disease Pathophysiology. Sleep Med Clin. 2015;10:207\u201314 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556407X15000570 [cited 2020 Sep 12]. W.B. Saunders.","journal-title":"Sleep Med Clin"},{"key":"3175_CR11","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1177\/1060028018760296","volume":"52","author":"E Patatanian","year":"2018","unstructured":"Patatanian E, Claborn MK. Drug-Induced Restless Legs Syndrome. Ann Pharmacother. 2018;52:662\u201372 Available from: http:\/\/journals.sagepub.com\/doi\/10.1177\/1060028018760296 [cited 2020 Sep 13] SAGE Publications Inc.","journal-title":"Ann Pharmacother"},{"key":"3175_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sleep.2016.01.017","volume":"21","author":"D Garcia-Borreguero","year":"2016","unstructured":"Garcia-Borreguero D, Silber MH, Winkelman JW, H\u00f6gl B, Bainbridge J, Buchfuhrer M, et al. Guidelines for the first-line treatment of restless legs syndrome\/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1\u201311. https:\/\/doi.org\/10.1016\/j.sleep.2016.01.017.","journal-title":"Sleep Med"},{"issue":"2","key":"3175_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345 Available from: https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full\/10.1038\/clpt.1981.154 [cited 2020 Sep 12].","journal-title":"Clin Pharmacol Ther"},{"key":"3175_CR14","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1111\/bph.12720","volume":"171","author":"B Guardiola-Lemaitre","year":"2014","unstructured":"Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Moca\u00ebr E. Agomelatine: Mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol. 2014;171:3604\u201319 Available from: \/pmc\/articles\/PMC4128060\/. [cited 2021 Mar 10]. John Wiley and Sons Inc.","journal-title":"Br J Pharmacol"},{"key":"3175_CR15","doi-asserted-by":"crossref","unstructured":"Demyttenaere K. Agomelatine: A narrative review, Eur Neuropsychopharmacol; 2011. Vol. 21. p. S703\u2013S709. Elsevier.","DOI":"10.1016\/j.euroneuro.2011.07.004"},{"issue":"10128","key":"3175_CR16","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357\u201366 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29477251\/ [cited 2020 Sep 24].","journal-title":"Lancet"},{"issue":"2","key":"3175_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1517\/14656566.2014.862233","volume":"15","author":"SE Macisaac","year":"2014","unstructured":"Macisaac SE, Carvalho AF, Cha DS, Mansur RB, McIntyre RS. The mechanism, efficacy, and tolerability profile of agomelatine. Expert Opin Pharmacother. 2014;15(2):259\u201374 Available from: http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.2014.862233 [cited 2020 Sep 21].","journal-title":"Expert Opin Pharmacother"},{"key":"3175_CR18","unstructured":"Annex I Summary Of Product Characteristics. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/valdoxan-epar-product-information_en.pdf."},{"key":"3175_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/00003088-200746040-00002","volume":"46","author":"N Rao","year":"2007","unstructured":"Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46:281\u201390 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17375980\/ [cited 2021 Mar 18].","journal-title":"Clin Pharmacokinet"},{"key":"3175_CR20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2147\/NDT.S67470","volume":"11","author":"MN Levitan","year":"2015","unstructured":"Levitan MN, Papelbaum M, Nardi AE. Profile of agomelatine and its potential in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2015;11:1149\u201355 Available from: \/pmc\/articles\/PMC4427071\/ [cited 2021 Mar 18]. Dove Medical Press Ltd.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3175_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/hup.918","volume":"23","author":"PM Haddad","year":"2008","unstructured":"Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: Clinical features and management. Hum Psychopharmacol. 2008;23:15\u201326 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18098217\/ [cited 2020 Sep 24].","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"3175_CR22","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1331\/JAPhA.2009.08083","volume":"49","author":"LP Koliscak","year":"2009","unstructured":"Koliscak LP, Makela EH. Selective serotonin reuptake inhibitor-induced akathisia. J Am Pharm Assoc. 2009;49(2):e28\u201338 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319115309614 [cited 2020 Sep 14].","journal-title":"J Am Pharm Assoc"},{"issue":"4","key":"3175_CR23","first-page":"533","volume":"13","author":"J Volpi-Abadie","year":"2013","unstructured":"Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013;13(4):533\u201340 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24358002 [cited 2021 Mar 2].","journal-title":"Ochsner J"},{"issue":"3","key":"3175_CR24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5664\/jcsm.5574","volume":"12","author":"TA Roehrs","year":"2016","unstructured":"Roehrs TA, Roth T. Gender differences in the efficacy and safety of chronic nightly zolpidem. J Clin Sleep Med. 2016;12(3):319\u201325 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26446253\/ [cited 2021 Mar 2].","journal-title":"J Clin Sleep Med"},{"issue":"8","key":"3175_CR25","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881111424455","volume":"26","author":"TA Roehrs","year":"2012","unstructured":"Roehrs TA, Randall S, Harris E, Maan R, Roth T. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: A prospective placebo-controlled study. J Psychopharmacol. 2012;26(8):1088\u201395 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22004689\/ [cited 2021 Mar 2].","journal-title":"J Psychopharmacol"},{"key":"3175_CR26","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.4088\/JCP.v65n0918g","volume":"65","author":"CL Kao","year":"2004","unstructured":"Kao CL, Huang SC, Yang YJ, Tsai SJ. A case of parenteral zolpidem dependence with opioid-like withdrawal symptoms. J Clin Psychiatry. 2004;65:1287 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/15367062\/ [cited 2021 Mar 2].","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"3175_CR27","first-page":"76","volume":"23","author":"LJ Wang","year":"2011","unstructured":"Wang LJ, Ree SC, Chu CL, Juang YY. Zolpidem dependence and withdrawal seizure - report of two cases. Psychiatr Danub. 2011;23(1):76\u20138.","journal-title":"Psychiatr Danub"},{"key":"3175_CR28","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jama.1994.03520220015010","volume":"272","author":"CA Gericke","year":"1994","unstructured":"Gericke CA, Ludolph AC. Chronic Abuse of Zolpidem. JAMA. 1994;272:1721\u20132 Available from: https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/383839 [cited 2021 Mar 2].","journal-title":"JAMA"},{"key":"3175_CR29","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/0140-6736(93)91522-N","volume":"342","author":"R Cavallaro","year":"1993","unstructured":"Cavallaro R, Grazia Regazzetti M, Covelli G, Smeraldi E. Tolerance and withdrawal with zolpidem. Lancet. 1993;342:374\u20135 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/014067369391522N [cited 2021 Mar 2].","journal-title":"Lancet"},{"issue":"11","key":"3175_CR30","first-page":"1006","volume":"18","author":"M Heydari","year":"2013","unstructured":"Heydari M, Isfeedvajani MS. Zolpidem dependence, abuse and withdrawal: A case report. J Res Med Sci. 2013;18(11):1006\u20137 Available from: \/pmc\/articles\/PMC3906775\/ [cited 2021 Mar 2].","journal-title":"J Res Med Sci"},{"issue":"8","key":"3175_CR31","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/brain\/awl163","volume":"129","author":"S \u010cervenka","year":"2006","unstructured":"\u010cervenka S, P\u00e5lhagen SE, Comley RA, Panagiotidis G, Csel\u00e9nyi Z, Matthews JC, et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain. 2006;129(8):2017\u201328 Available from: https:\/\/academic.oup.com\/brain\/article\/129\/8\/2017\/334696 [cited 2020 Sep 22].","journal-title":"Brain"},{"issue":"2","key":"3175_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/npp.2012.140","volume":"38","author":"F Chenu","year":"2013","unstructured":"Chenu F, El Mansari M, Blier P. Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacology. 2013;38(2):275\u201384 Available from: www.neuropsychopharmacology.org [cited 2020 Sep 24].","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"3175_CR33","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/ana.10843","volume":"55","author":"M Michaud","year":"2004","unstructured":"Michaud M, Dumont M, Selmaoui B, Paquet J, Fantini ML, Montplaisir J. Circadian Rhythm of Restless Legs Syndrome: Relationship with Biological Markers. Ann Neurol. 2004;55(3):372\u201380 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/14991815\/ [cited 2020 Sep 22].","journal-title":"Ann Neurol"},{"issue":"1","key":"3175_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4103\/0019-5545.105515","volume":"55","author":"R Gupta","year":"2013","unstructured":"Gupta R, Lahan V, Goel D. Prevalence of restless leg syndrome in subjects with depressive disorder. Indian J Psychiatry. 2013;55(1):70\u20133 Available from: \/pmc\/articles\/PMC3574459\/?report=abstract [cited 2020 Sep 24].","journal-title":"Indian J Psychiatry"},{"issue":"1","key":"3175_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1176\/jnp.2008.20.1.101","volume":"20","author":"HB Lee","year":"2008","unstructured":"Lee HB, Hening WA, Allen RP, Kalaydjian AE, Earley CJ, Eaton WW, et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatr Clin Neurosci. 2008;20(1):101\u20135 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18305292\/ [cited 2020 Sep 26].","journal-title":"J Neuropsychiatr Clin Neurosci"},{"issue":"12","key":"3175_CR36","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1002\/mds.22701","volume":"24","author":"E Driver-Dunckley","year":"2009","unstructured":"Driver-Dunckley E, Connor D, Hentz J, Sabbagh M, Silverberg N, Hernandez J, et al. No evidence for cognitive dysfunction or depression in patients with mild restless legs syndrome. Mov Disord. 2009;24(12):1843\u20137 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19609905\/ [cited 2020 Sep 26].","journal-title":"Mov Disord"},{"key":"3175_CR37","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/ijnp\/pyx056","volume":"20","author":"P Belujon","year":"2017","unstructured":"Belujon P, Grace AA. Dopamine system dysregulation in major depressive disorders. Int J Neuropsychopharmacol. 2017;20:1036\u201346 Available from: \/pmc\/articles\/PMC5716179\/?report=abstract [cited 2020 Sep 26]. Oxford University Press.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"3175_CR38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12888-020-02711-z","volume":"20","author":"A Revet","year":"2020","unstructured":"Revet A, Revet A, Revet A, Montastruc F, Montastruc F, Montastruc F, et al. Antidepressants and movement disorders: A postmarketing study in the world pharmacovigilance database. BMC Psychiatry. 2020;20(1):308. https:\/\/doi.org\/10.1186\/s12888-020-02711-z [cited 2020 Sep 24].","journal-title":"BMC Psychiatry"},{"issue":"1","key":"3175_CR39","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jpsychires.2008.02.006","volume":"43","author":"KG Rottach","year":"2008","unstructured":"Rottach KG, Schaner BM, Kirch MH, Zivotofsky AZ, Teufel LM, Gallwitz T, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res. 2008;43(1):70\u20135 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18468624\/ [cited 2020 Sep 24].","journal-title":"J Psychiatr Res"},{"key":"3175_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.sleep.2017.12.003","volume":"47","author":"W Ondo","year":"2018","unstructured":"Ondo W. Restless Legs Syndrome \u201cPatient Odyssey\u201d survey of disease burden on patient and spouses\/partners. Sleep Med. 2018;47:51\u20133 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29753925\/ [cited 2020 Sep 26].","journal-title":"Sleep Med"},{"issue":"3","key":"3175_CR41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.sleep.2008.01.002","volume":"10","author":"S Happe","year":"2009","unstructured":"Happe S, Reese JP, Stiasny-Kolster K, Peglau I, Mayer G, Klotsche J, et al. Assessing health-related quality of life in patients with restless legs syndrome. Sleep Med. 2009;10(3):295\u2013305 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945708000117 [cited 2020 Sep 16].","journal-title":"Sleep Med"},{"issue":"10","key":"3175_CR42","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.sleep.2010.08.006","volume":"11","author":"B Benediktsdottir","year":"2010","unstructured":"Benediktsdottir B, Janson C, Lindberg E, Arnard\u00f3ttir ES, Olafsson I, Cook E, et al. Prevalence of restless legs syndrome among adults in Iceland and Sweden: Lung function, comorbidity, ferritin, biomarkers and quality of life. Sleep Med. 2010;11(10):1043\u20138 Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945710003412 [cited 2020 Sep 16].","journal-title":"Sleep Med"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03175-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-021-03175-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03175-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T07:04:37Z","timestamp":1617779077000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-021-03175-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3175"],"URL":"https:\/\/doi.org\/10.1186\/s12888-021-03175-5","relation":{},"ISSN":["1471-244X"],"issn-type":[{"type":"electronic","value":"1471-244X"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"6 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient provided signed consent for participation and publication of this article. The proposal was accepted by the international review board (IRB) at Hamad Medical Corporation (Protocol ID: MRC-04-20874).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient signed written informed consent for publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P.M.H. reports personal fees from Janssen, Lundbeck, Otsuka, NewBridge Pharmaceuticals and Sunovion, outside the submitted work. The other authors report no conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}